Biogen pays $125M for mid-stage, experimental multiple sclerosis drug
If approved, the drug would be Biogen's seventh for MS.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Rowan Walrath Source Type: news